OnKure Therapeutics, Inc.(OKUR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OKUR OnKure Therapeutics, Inc.

盘前交易 09-15 06:21:37 EDT

3.00

-0.10

-3.23%

最高3.14	最低2.98	成交量10.52万
今开3.11	昨收3.10	日振幅5.23%
总市值1.21亿	流通市值1.11亿	总股本4,040万
成交额31.97万	换手率0.28%	流通股本3,697万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OKUR","market":"US","secType":"STK","nameCN":"OnKure Therapeutics, Inc.","latestPrice":3,"timestamp":1789416000000,"preClose":3.1,"halted":0,"volume":105157,"delay":0,"changeRate":-0.03225806451612906,"floatShares":36969428,"shares":40395500,"eps":-3.4954,"marketStatus":"盘前交易","change":-0.1,"latestTime":"09-15 06:21:37 EDT","open":3.11,"high":3.14,"low":2.978,"amount":319658,"amplitude":0.052258,"askPrice":4.8,"askSize":200,"bidPrice":2.52,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.4954,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"listingDate":1617940800000,"exchange":"NASDAQ","adjPreClose":3,"postHourTrading":{"tag":"盘后","latestPrice":3,"preClose":3,"latestTime":"16:10 EDT","volume":2562,"amount":7686,"timestamp":1789416603986,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6716644797963711,"impliedVol":0.6175,"impliedVolPercentile":0.7368},"requestUrl":"/m/hq/s/OKUR","defaultTab":"news","newsList":[{"id":"1190631197","title":"OnKure Therapeutics拟通过Leerink Partners注册发行高达1亿美元A类普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1190631197","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190631197?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:49","pubTimestamp":1785876551,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics, Inc.（股票代码：OKUR）今日向美国证券交易委员会（SEC）提交文件，正式注册了一项高达1亿美元的A类普通股发行与销售计划。此次发行将由Leerink Partners担任承销商，具体销售条款与时间表尚未最终确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKUR","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179235499","title":"Onkure Therapeutics 宣布超额认购1.5亿美元私募融资，以推进新一代Pi3kα泛突变选择性抑制剂在乳腺癌及血管异常领域的研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1179235499","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179235499?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:04","pubTimestamp":1774613094,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics 近日公布一项获得超额认购的1.5亿美元私募融资计划，所筹资金将主要用于加速其新一代Pi3kα泛突变选择性抑制剂在乳腺癌和血管异常适应症中的临床开发进程。该融资得到多家知名投资机构支持，反映出市场对其创新疗法前景的强烈信心。\n公司表示，这笔资金将有力推动其核心候选药物走向临床后期研究，为相关疾病患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","OKUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518746364","title":"奥本海默：维持OnKure Therapeutics(OKUR.US)评级，由优于大市调整至优于大市评级, 目标价由35.00美元调整至30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518746364","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518746364?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:41","pubTimestamp":1741696890,"startTime":"0","endTime":"0","summary":"奥本海默：维持OnKure Therapeutics(OKUR.US)评级，由优于大市调整至优于大市评级, 目标价由35.00美元调整至30.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11204148668013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","OKUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518789118","title":"OnKure Therapeutics(OKUR.US)：2024年Q4财报实现营收0美元；每股收益为-1.37美元，前值为-30.14美元，预期值为-0.74美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789118","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518789118?lang=zh_cn&edition=full","pubTime":"2025-03-11 05:45","pubTimestamp":1741643101,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics(OKUR.US)：2024年Q4财报实现营收0美元；每股收益为-1.37美元，前值为-30.14美元，预期值为-0.74美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11054548643205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","OKUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104892081","title":"OnKure Therapeutics 2024年第四季度GAAP每股收益$(1.37)未达到$(0.74)的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1104892081","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104892081?lang=zh_cn&edition=full","pubTime":"2025-03-11 04:14","pubTimestamp":1741637672,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics(LENZ) (NASDAQ:OKUR)报告的季度每股亏损为$(1.37)，未达到分析师普遍预期的$(0.74)，低于预期85.14%。以上内容来自Benzinga Earnings专栏，原文如下：OnKure $Therapeutics(LENZ)$ (NASDAQ:OKUR) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(0.74) by 85.14 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onkure.com;investors.onkuretherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.162},{"period":"1month","weight":-0.2481},{"period":"3month","weight":-0.2941},{"period":"6month","weight":-0.2519},{"period":"1year","weight":0.2245},{"period":"ytd","weight":0.0345}],"compareEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.0199},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.1504},{"period":"1year","weight":0.1574},{"period":"ytd","weight":0.1158}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"OnKure Therapeutics, Inc.于2014年9月22日在特拉华州注册成立。OnKure是一家临床阶段的生物制药公司，专注于发现和开发同类最佳的精准药物，这些药物针对可获得的疗法服务不足的癌症的生物验证驱动因素。使用基于结构的药物设计平台，OnKure正在构建一个强大的肿瘤不可知性候选药物管道，这些候选药物旨在实现最佳疗效和耐受性。OnKure正在开发OKI-219，一种选择性PI3K α H1047R抑制剂，作为其先导项目。OnKure的目标是成为靶向致癌PI3K α的领导者，并拥有多个旨在实现这一关键癌基因的同类最佳靶向的项目。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.092027},{"month":2,"riseRate":0.6,"avgChangeRate":-0.049012},{"month":3,"riseRate":0.6,"avgChangeRate":0.191785},{"month":4,"riseRate":0.6,"avgChangeRate":0.071237},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.136671},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.005239},{"month":7,"riseRate":0.333333,"avgChangeRate":0.030522},{"month":8,"riseRate":0.333333,"avgChangeRate":0.030264},{"month":9,"riseRate":0.5,"avgChangeRate":-0.003912},{"month":10,"riseRate":0.8,"avgChangeRate":0.05116},{"month":11,"riseRate":0.2,"avgChangeRate":-0.152993},{"month":12,"riseRate":0.4,"avgChangeRate":-0.187777}],"exchange":"NASDAQ","name":"OnKure Therapeutics, Inc.","nameEN":"OnKure Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OnKure Therapeutics, Inc.(OKUR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供OnKure Therapeutics, Inc.(OKUR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"OnKure Therapeutics, Inc.,OKUR,OnKure Therapeutics, Inc.股票,OnKure Therapeutics, Inc.股票老虎,OnKure Therapeutics, Inc.股票老虎国际,OnKure Therapeutics, Inc.行情,OnKure Therapeutics, Inc.股票行情,OnKure Therapeutics, Inc.股价,OnKure Therapeutics, Inc.股市,OnKure Therapeutics, Inc.股票价格,OnKure Therapeutics, Inc.股票交易,OnKure Therapeutics, Inc.股票购买,OnKure Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OnKure Therapeutics, Inc.(OKUR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供OnKure Therapeutics, Inc.(OKUR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}